Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.
Fineman MS, McAlindon TE, Lattermann C, Swearingen CJ, Kennedy S, Lopez VA, Simsek I, Tambiah JRS, Yazici Y. Fineman MS, et al. Among authors: swearingen cj. Rheumatol Ther. 2023 Dec;10(6):1741-1752. doi: 10.1007/s40744-023-00604-7. Epub 2023 Oct 30. Rheumatol Ther. 2023. PMID: 37902943 Free PMC article.
Associations of Cost Sharing With Rheumatoid Arthritis Disease Burden.
Dowell S, Swearingen CJ, Pedra-Nobre M, Wollaston D, Najmey S, Elliott CL, Ford TL, North H, Dore R, Dolatabadi S, Ramanujam T, Kennedy S, Ott S, Jileaeva I, Richardson A, Wright G, Kerr GS. Dowell S, et al. Among authors: swearingen cj. ACR Open Rheumatol. 2023 Aug;5(8):381-387. doi: 10.1002/acr2.11575. Epub 2023 Jun 19. ACR Open Rheumatol. 2023. PMID: 37334885 Free PMC article.
A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. Yazici Y, et al. Among authors: swearingen cj. Osteoarthritis Cartilage. 2021 May;29(5):654-666. doi: 10.1016/j.joca.2021.02.004. Epub 2021 Feb 12. Osteoarthritis Cartilage. 2021. PMID: 33588087 Free article. Clinical Trial.
Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Yazici Y, et al. Among authors: swearingen cj. Arthritis Rheumatol. 2020 Oct;72(10):1694-1706. doi: 10.1002/art.41315. Epub 2020 Sep 6. Arthritis Rheumatol. 2020. PMID: 32432388 Free PMC article. Clinical Trial.
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B, Mittapalli GK, Lai C, Duong-Polk K, Stewart J, Güner B, Hofilena B, Tjitro A, Anderson SD, Herman DS, Dellamary L, Swearingen CJ, Sunil KC, Yazici Y. Melchior B, et al. Among authors: swearingen cj. Aging Cell. 2019 Oct;18(5):e13000. doi: 10.1111/acel.13000. Epub 2019 Jul 3. Aging Cell. 2019. PMID: 31267651 Free PMC article.
A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, Skrepnik N, Armas E, Swearingen CJ, DiFrancesco A, Tambiah JRS, Hood J, Hochberg MC. Yazici Y, et al. Among authors: swearingen cj. Osteoarthritis Cartilage. 2017 Oct;25(10):1598-1606. doi: 10.1016/j.joca.2017.07.006. Epub 2017 Jul 13. Osteoarthritis Cartilage. 2017. PMID: 28711582 Free article. Clinical Trial.
67 results